CTRI/2017/02/007837Not yet recruitingPhase 4
Multicentric Study onPersistence of Immune Responses of anti-HAV in Children vaccinated with live attenuated Hepatitis A vaccine Biovac-A TM Upto 9 years
Wockhardt Ltd0 sites150 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •1. Subjects who were enrolled for the Multi-centric Trial on Immunogenecity of single dose of Biovac-ATM Live Attenuated Hepatitis-A Vaccine (MC/Vaccine/2006/CT-01) in 2007 would be considered
- •2. Subjects who had a baseline anti-HAV antibody titre <20mIU/mL in the initial phase of the study (MC/Vaccine/2006/CT-01).
- •3. Written informed consent from the parent or guardian of the subjects.
Exclusion Criteria
- •1. Subjects who had a baseline anti-HAV antibody titre >20mIU/mL(i.e these subjects are considered to be seroprotected prior to vaccination)
Investigators
Similar Trials
Recruiting
Phase 4
Evaluation of immunogenicity of Single dose Live Attenuated Varicella VaccineCTRI/2015/02/005522Wockhardt Ltd
Recruiting
Not Applicable
Multi-institutional study of immunologic response tu surgical stress in patients undergoing pulmonary lobectomyung cancerJPRN-UMIN000021182agoya City University100
Active, not recruiting
Phase 1
Administration of 9valent vaccine against papillomavirus in HIV-positive womeEUCTR2018-000228-33-BECHU Saint-Pierre200
Completed
Not Applicable
A cross-sectional study on the immunological properties of the cow's milk protein hydrolysates and hydrolyzed formulas using blood samples from children with cow's milk allergyCow's milk allergyJPRN-UMIN000046543Kanagawa Chidren's Medical Center10
Active, not recruiting
Not Applicable
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600